Professur für Endokrinologie

Rapid Evolution of Metastases in Patients with Treated G3 Neuroendocrine Tumors Associated with NEC-Like Transformation and TP53 Mutation (2024) Kasajima A, Pfarr N, Mayr EM, Ura A, Moser E, von Werder A, Agaimy A, et al. Journal article A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation Center. (2024) Cuba L, Dürr P, Geßner K, Häcker B, Fietkau R, Siebler J, Pavel ME, et al. Journal article Immuntherapie bei neuroendokrinen Tumoren: Zeitpunkt und Zielgruppe (2022) Auernhammer CJ, Pavel ME Journal article Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT (2022) Zwirtz K, Hardt J, Acker G, Baur ADJ, Pavel ME, Huang K, Brenner W, Prasad V Journal article Neuroendocrine Tumor Treatments and Follow-up Disease Management: Comparative Perspective (US and Canada vs Global) (2022) Kolarova T, Hollander R, Mcdonnell M, Bouvier C, Pavel ME, Singh H, Howe J, et al. Conference contribution Subtype specific expression of radioligand targets in the prospective Real World clinico-pathological register trial BRIDGister (2022) Wirtz R, Friedersdorff F, Barski D, Otto T, Bug R, Veltrup E, Kilic E, et al. Conference contribution An easily expandable multi-drug LC-MS assay for the simultaneous quantification of 57 oral antitumor drugs in human plasma (2021) Kehl N, Schlichtig K, Dürr P, Bellut L, Dörje F, Fietkau R, Pavel ME, et al. Journal article Corrigendum to "Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 32 (2021) 439-451 (2021) Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, et al. Journal article, Erratum The Phase 3 NETTER-1 Study of [Lu-177]Lu-DOTA-TATE in Patients with Midgut Neuroendocrine Tumours: Final Overall Survival and Long-Term Renal Safety (2021) Kunz P, Caplin ME, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, et al. Conference contribution Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumor (NET) Patients (SCAN): PRRT in the Treatment of Neuroendocrine Tumor (NET) Patients (2021) Dureja S, Kolarova T, Mcdonnell M, Van Genechten D, Bouvier C, Gellerman E, O'Toole D, et al. Conference contribution